China Biologic Products Inc. (NASDAQ:CBPO) fell 1.5% during mid-day trading on Monday . The company traded as low as $123.57 and last traded at $123.76, with a volume of 92,368 shares traded. The stock had previously closed at $125.64.

A number of brokerages have issued reports on CBPO. Jefferies Group reaffirmed a “buy” rating on shares of China Biologic Products in a research report on Saturday, June 4th. Credit Suisse Group AG raised shares of China Biologic Products from a “neutral” rating to an “outperform” rating in a research report on Tuesday, July 5th. Finally, Zacks Investment Research raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a research report on Thursday, May 19th.

The company has a market cap of $3.37 billion and a PE ratio of 36.11. The firm’s 50-day moving average price is $116.04 and its 200-day moving average price is $115.51.

China Biologic Products (NASDAQ:CBPO) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported $1.26 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.10. The company earned $91.40 million during the quarter, compared to analysts’ expectations of $87.60 million. During the same period in the prior year, the business posted $1.06 earnings per share. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. On average, equities analysts anticipate that China Biologic Products Inc. will post $4.32 EPS for the current year.

In other news, Director Wp X. Biologics Llc sold 2,775,000 shares of the firm’s stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $111.00, for a total value of $308,025,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Ming Yang sold 13,908 shares of the firm’s stock in a transaction dated Friday, May 20th. The stock was sold at an average price of $113.64, for a total transaction of $1,580,505.12. Following the completion of the sale, the chief financial officer now directly owns 52,282 shares of the company’s stock, valued at $5,941,326.48. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in China Biologic Products stock. Employees Retirement System of Texas bought a new stake in China Biologic Products Inc. (NASDAQ:CBPO) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,846,000. Employees Retirement System of Texas owned 0.08% of China Biologic Products as of its most recent SEC filing.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.